Zygel - Zynerba
Reassessing Zynerba Pharmaceuticals (NASDAQ:ZYNE) | Seeking Alpha
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Stock is a Medical Cannabis Investment You Can Feel Good About
Zynerba Pharmaceuticals Inc receives guidance from the US Food and Drug Administration on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome
BRAIN Industry Spotlight: Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders
Zynerba Synthetic CBD Gel for Epilepsy Proves Safe but Not Effective in FDA Phase 2 Trial – New Cannabis Ventures
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th | ZYNE Stock News
g260361mmi008.gif
Zynerba hopes to crack fragile X at last | Evaluate
Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products
Stan Banks - Director of CMC and Product Development - Zynerba Pharmaceuticals | LinkedIn
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
EDGAR Filing Documents for 0001104659-22-128854
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba: Repeated Trial Failures, Some Post Hoc Success (NASDAQ:ZYNE) | Seeking Alpha
